Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

Not every enlarged prostate needs treatment. China's 2025 BPH guideline sets out how severity is scored, which drugs suit which prostate size, and the specific complications that make surgery the right answer.

What this guide covers: How severity is assessed · Watchful waiting is a real option · Drug treatment, matched to the prostate · When surgery is the right answer

Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate that presses on the urethra and produces lower urinary tract symptoms. It is close to universal with age: more than half of men over 60 are affected, and the figure approaches 80 percent beyond 80. The symptoms fall into two groups — voiding symptoms such as a weak stream, hesitancy and a sensation of incomplete emptying, and storage symptoms such as frequency, urgency and nocturia.

China's 2025 urology guideline on BPH moves the decision-making away from habit and toward measured severity, prostate size and the risk of progression.

How severity is assessed

The International Prostate Symptom Score is the standard instrument: seven questions, each scored 0 to 5, giving a total of 0 to 35, with 0 to 7 as mild, 8 to 19 as moderate and 20 to 35 as severe. A quality-of-life score is recorded alongside it. The guideline notes that the questionnaire should be completed by the patient, because clinician-completed scores systematically differ.

A digital rectal examination remains the first-line physical assessment. It cannot measure volume accurately — the error can be 30 percent — but it detects nodularity and hardness that would raise concern about cancer. Transrectal or abdominal ultrasound provides the volume, calculated as length times width times height times 0.52, and the post-void residual. Serum PSA is measured to screen for prostate cancer, interpreted against age and prostate size. Urodynamics is reserved for cases where bladder function is in doubt or where symptoms and obstruction do not match.

Watchful waiting is a real option

Men with mild symptoms, a prostate under about 30 mL and a PSA below 1.5 ng/mL can be managed with review every 6 to 12 months plus lifestyle changes: cutting caffeine and alcohol, not holding urine deliberately, reducing evening fluid, and pelvic floor training. Certain medicines — anticholinergics and some calcium channel blockers — can worsen retention and should be reviewed.

Drug treatment, matched to the prostate

Alpha-1 blockers relax smooth muscle at the bladder neck and prostate and work within one to two weeks. Tamsulosin is the usual choice because it causes less postural hypotension than non-selective agents. They suit men with moderate voiding symptoms and a prostate under about 40 mL.

5-alpha-reductase inhibitors — finasteride or dutasteride — shrink the gland by roughly 20 to 30 percent over 12 months and suit men with a larger prostate or evidence of progression. They take months to work and must be continued. Combination therapy is recommended for men at higher risk of progression and reduces the chance of acute retention substantially.

Antimuscarinics such as tolterodine or solifenacin help men whose storage symptoms dominate, but must not be used when post-void residual is large or the detrusor is weak.

When surgery is the right answer

Clear indications include two or more episodes of acute urinary retention, recurrent urinary tract infection, recurrent visible haematuria that medicine does not control, bladder stones, upper tract dilatation or impaired renal function, and severe symptoms that have not responded to drugs.

Transurethral resection of the prostate remains the reference operation for glands under about 80 mL. Holmium laser enucleation removes tissue along the capsule and has a low recurrence rate with less bleeding, which makes it suitable for men on anticoagulants. The guideline's message on surgery is that it should follow defined indications rather than convenience, and the choice of technique should match gland size, bleeding risk and the surgeon's experience.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.